GB939516A
(en)
|
1961-05-29 |
1963-10-16 |
British Drug Houses Ltd |
Sulphonyl ureas
|
US3702849A
(en)
|
1967-10-26 |
1972-11-14 |
Pfizer |
4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
|
US3752660A
(en)
|
1971-03-15 |
1973-08-14 |
Allied Chem |
Chlorophenoxyacetyloxazolidone herbicides and preparation thereof
|
US4436748A
(en)
|
1980-10-20 |
1984-03-13 |
Hoechst-Roussel Pharmaceuticals Inc. |
Benzo[b]thiophenes
|
US4439606A
(en)
|
1982-05-06 |
1984-03-27 |
American Cyanamid Company |
Antiatherosclerotic 1-piperazinecarbonyl compounds
|
EP0094498A3
(en)
|
1982-05-06 |
1985-04-03 |
American Cyanamid Company |
Antiatherosclerotic 1-piperazine derivatives
|
US4656181A
(en)
|
1982-11-24 |
1987-04-07 |
Cermol S.A. |
Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
|
JPS59163372A
(en)
|
1983-03-09 |
1984-09-14 |
Showa Denko Kk |
Pyrazole derivative, its preparation and herbicide
|
JPS60193955A
(en)
|
1984-03-13 |
1985-10-02 |
Mitsui Toatsu Chem Inc |
Cyclic unsaturated amide-substituted ether compound and its preparation
|
JPS6143190A
(en)
|
1984-08-06 |
1986-03-01 |
Mitsui Petrochem Ind Ltd |
Pyridopyrimidine derivative and preparation thereof
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
FR2588189B1
(en)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
US5010175A
(en)
|
1988-05-02 |
1991-04-23 |
The Regents Of The University Of California |
General method for producing and selecting peptides with specific properties
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US5925525A
(en)
|
1989-06-07 |
1999-07-20 |
Affymetrix, Inc. |
Method of identifying nucleotide differences
|
IE66205B1
(en)
|
1990-06-14 |
1995-12-13 |
Paul A Bartlett |
Polypeptide analogs
|
US5650489A
(en)
|
1990-07-02 |
1997-07-22 |
The Arizona Board Of Regents |
Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
|
JP2594486B2
(en)
|
1991-01-15 |
1997-03-26 |
アルコン ラボラトリーズ インコーポレイテッド |
Topical ophthalmic composition
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
US6051380A
(en)
|
1993-11-01 |
2000-04-18 |
Nanogen, Inc. |
Methods and procedures for molecular biological analysis and diagnostics
|
US6017696A
(en)
|
1993-11-01 |
2000-01-25 |
Nanogen, Inc. |
Methods for electronic stringency control for molecular biological analysis and diagnostics
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
US5288514A
(en)
|
1992-09-14 |
1994-02-22 |
The Regents Of The University Of California |
Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5605798A
(en)
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
US6045996A
(en)
|
1993-10-26 |
2000-04-04 |
Affymetrix, Inc. |
Hybridization assays on oligonucleotide arrays
|
US6068818A
(en)
|
1993-11-01 |
2000-05-30 |
Nanogen, Inc. |
Multicomponent devices for molecular biological analysis and diagnostics
|
US5538848A
(en)
|
1994-11-16 |
1996-07-23 |
Applied Biosystems Division, Perkin-Elmer Corp. |
Method for detecting nucleic acid amplification using self-quenching fluorescence probe
|
IL111730A
(en)
|
1993-11-29 |
1998-12-06 |
Fujisawa Pharmaceutical Co |
Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
|
AU694187B2
(en)
|
1994-02-07 |
1998-07-16 |
Beckman Coulter, Inc. |
Ligase/polymerase-mediated genetic bit analysis TM of single nucleotide polymorphisms and its use in genetic analysis
|
US5593853A
(en)
|
1994-02-09 |
1997-01-14 |
Martek Corporation |
Generation and screening of synthetic drug libraries
|
US5539083A
(en)
|
1994-02-23 |
1996-07-23 |
Isis Pharmaceuticals, Inc. |
Peptide nucleic acid combinatorial libraries and improved methods of synthesis
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
WO1996013262A1
(en)
|
1994-10-27 |
1996-05-09 |
Merck & Co., Inc. |
Muscarine antagonists
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
FR2734816B1
(en)
|
1995-05-31 |
1997-07-04 |
Adir |
NOVEL ARYL (ALKYL) PROPYLAMIDES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
DE69638269D1
(en)
|
1995-06-14 |
2010-11-18 |
Univ California |
HIGH-AFFINE HUMAN ANTIBODY AGAINST TUMORANTIGENE
|
ATE225343T1
(en)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
MATRIX METALLOPROTEASE INHIBITORS
|
US6011029A
(en)
|
1996-02-26 |
2000-01-04 |
Bristol-Myers Squibb Company |
Inhibitors of farnesyl protein transferase
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
DE69712496T2
(en)
|
1996-07-18 |
2002-08-29 |
Pfizer |
MATRIX METALLOPROTEASE INHIBITORS BASED ON PHOSPHINIC ACIDS
|
KR20000068248A
(en)
|
1996-08-23 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
Arylsulfonylamino Hydroxamic Acid Derivatives
|
US5777324A
(en)
|
1996-09-19 |
1998-07-07 |
Sequenom, Inc. |
Method and apparatus for maldi analysis
|
PT950059E
(en)
|
1997-01-06 |
2004-10-29 |
Pfizer |
CYCLIC SULFONA DERIVATIVES
|
US6303636B1
(en)
|
1997-02-03 |
2001-10-16 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
GB9702194D0
(en)
|
1997-02-04 |
1997-03-26 |
Lilly Co Eli |
Sulphonide derivatives
|
AU5493598A
(en)
|
1997-02-07 |
1998-08-26 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
BR9807678A
(en)
|
1997-02-11 |
2000-02-15 |
Pfizer |
Derivatives of arylsulfonyl hydroxamic acids
|
WO1998035951A2
(en)
|
1997-02-17 |
1998-08-20 |
Fujisawa Pharmaceutical Co., Ltd. |
New aminopiperazine derivatives
|
UA73073C2
(en)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Substituted 3-cyan chinolines
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US5919626A
(en)
|
1997-06-06 |
1999-07-06 |
Orchid Bio Computer, Inc. |
Attachment of unmodified nucleic acids to silanized solid phase surfaces
|
WO1998057948A1
(en)
|
1997-06-17 |
1998-12-23 |
Schering Corporation |
Novel n-substituted urea inhibitors of farnesyl-protein transferase
|
CA2299355C
(en)
|
1997-08-08 |
2005-09-27 |
Pfizer Products Inc. |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
DE19756236A1
(en)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Novel piperazinyl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
|
IL136637A0
(en)
|
1997-12-22 |
2001-06-14 |
Du Pont Pharm Co |
Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
PA8469501A1
(en)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
|
PA8469401A1
(en)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
BICYCLE DERIVATIVES OF HYDROXAMIC ACID
|
AU754952B2
(en)
|
1998-06-24 |
2002-11-28 |
Illumina, Inc. |
Decoding of array sensors with microspheres
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
US6429027B1
(en)
|
1998-12-28 |
2002-08-06 |
Illumina, Inc. |
Composite arrays utilizing microspheres
|
US6586447B1
(en)
|
1999-04-01 |
2003-07-01 |
Pfizer Inc |
3,3-disubstituted-oxindole derivatives useful as anticancer agents
|
US6511993B1
(en)
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
EP1081137A1
(en)
|
1999-08-12 |
2001-03-07 |
Pfizer Products Inc. |
Selective inhibitors of aggrecanase in osteoarthritis treatment
|
KR100527265B1
(en)
|
1999-09-13 |
2005-11-09 |
뉴젠 테크놀로지스 인코포레이티드 |
Methods and compositions for linear isothermal amplification of polynucleotide sequences
|
TWI271406B
(en)
|
1999-12-13 |
2007-01-21 |
Eisai Co Ltd |
Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
KR20080009294A
(en)
|
2000-03-13 |
2008-01-28 |
와이어쓰 홀딩스 코포레이션 |
Pharmaceutical composition for treating or inhibiting colonic polyps comprising cyanoquinolines
|
MXPA02009312A
(en)
|
2000-03-21 |
2003-03-12 |
Procter & Gamble |
Heterocyclic side chain containing metalloprotease inhibitors.
|
HUP0301562A2
(en)
|
2000-06-05 |
2003-12-29 |
Dong A Pharm. Co., Ltd. |
Novel oxazolidinone derivatives and a process for the preparation thereof and pharmaceutical compositions containing them
|
TWI227231B
(en)
|
2000-07-12 |
2005-02-01 |
Novartis Ag |
4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
|
BR0113356A
(en)
|
2000-08-18 |
2004-04-20 |
Millennium Pharm Inc |
Quinazoline derivatives as kinase inhibitors
|
US6890747B2
(en)
|
2000-10-23 |
2005-05-10 |
Warner-Lambert Company |
Phosphoinositide 3-kinases
|
US7429599B2
(en)
|
2000-12-06 |
2008-09-30 |
Signal Pharmaceuticals, Llc |
Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
|
US20020169300A1
(en)
|
2001-01-30 |
2002-11-14 |
Waterman Marian L. |
Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1
|
JP2005511478A
(en)
|
2001-04-03 |
2005-04-28 |
メルク エンド カムパニー インコーポレーテッド |
N-substituted non-aryl heterocyclic amidyl NMDA / NR2B antagonist
|
EP1382603B1
(en)
|
2001-04-26 |
2008-07-23 |
Eisai R&D Management Co., Ltd. |
Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
|
JP2002371078A
(en)
|
2001-06-12 |
2002-12-26 |
Sankyo Co Ltd |
Quinoline derivative and quinolone derivative
|
EP1421071B1
(en)
|
2001-07-02 |
2009-11-18 |
High Point Pharmaceuticals, LLC |
Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
|
AU2002352444A1
(en)
|
2001-12-20 |
2003-07-09 |
Celltech R And D Limited |
Quinazolinedione derivatives
|
EP1348434A1
(en)
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
AU2003269242A1
(en)
|
2002-10-11 |
2004-05-04 |
Astrazeneca Ab |
1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
|
JP4608852B2
(en)
|
2002-10-15 |
2011-01-12 |
チッソ株式会社 |
Liquid crystalline vinyl ketone derivatives and polymers thereof
|
JP2004250329A
(en)
|
2002-12-26 |
2004-09-09 |
Dainippon Pharmaceut Co Ltd |
Isatin derivative
|
CA2516234A1
(en)
|
2003-02-21 |
2004-09-02 |
Pfizer Inc. |
N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
|
AU2004220321B2
(en)
|
2003-03-12 |
2010-02-25 |
Kudos Pharmaceuticals Ltd |
Phthalazinone derivatives
|
US20050119266A1
(en)
|
2003-10-01 |
2005-06-02 |
Yan Shi |
Pyrrolidine and piperidine derivatives as factor Xa inhibitors
|
SE0302811D0
(en)
|
2003-10-23 |
2003-10-23 |
Astrazeneca Ab |
Novel compounds
|
JP4923380B2
(en)
|
2003-12-22 |
2012-04-25 |
Jnc株式会社 |
Low refractive index anisotropic compounds, compositions and polymers or polymer compositions thereof
|
JP4932495B2
(en)
|
2004-01-23 |
2012-05-16 |
アムゲン インコーポレイテッド |
Compound and method of use
|
WO2005082892A2
(en)
|
2004-02-17 |
2005-09-09 |
Dr. Reddy's Laboratories Ltd. |
Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
|
US7368445B2
(en)
|
2004-03-01 |
2008-05-06 |
Eli Lilly And Company |
Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
|
GB0405628D0
(en)
|
2004-03-12 |
2004-04-21 |
Glaxo Group Ltd |
Novel compounds
|
JP4775259B2
(en)
|
2004-03-31 |
2011-09-21 |
味の素株式会社 |
Aniline derivative
|
US20060167044A1
(en)
|
2004-12-20 |
2006-07-27 |
Arnaiz Damian O |
Piperidine derivatives and their use as anti-inflammatory agents
|
US20090264415A2
(en)
|
2004-12-30 |
2009-10-22 |
Steven De Jonghe |
Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
|
GB0428475D0
(en)
|
2004-12-30 |
2005-02-02 |
4 Aza Bioscience Nv |
Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
|
TW200643015A
(en)
|
2005-03-11 |
2006-12-16 |
Akzo Nobel Nv |
2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
|
AU2006224765B2
(en)
|
2005-03-16 |
2012-02-09 |
F.Hoffmann-La Roche Ag |
CIS-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
|
JP2007016011A
(en)
|
2005-06-10 |
2007-01-25 |
Nippon Soda Co Ltd |
New nitrogen-containing heterocyclic compound having antioxidative activity and antioxidative agent containing the compound
|
CA2612788A1
(en)
|
2005-06-24 |
2006-12-28 |
Steven Cesar Alfons De Jonghe |
Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
|
US20090099186A1
(en)
|
2005-10-11 |
2009-04-16 |
Leonid Beigelman |
Inhibitors of viral replication
|
TW200800201A
(en)
|
2005-11-18 |
2008-01-01 |
Lilly Co Eli |
Pyrimidinyl benzothiophene compounds
|
JP2009519349A
(en)
|
2005-12-15 |
2009-05-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Compounds that modulate the CB2 receptor
|
RU2008132333A
(en)
|
2006-02-07 |
2010-03-20 |
Вайет (Us) |
11-BETA HSD1 INHIBITORS
|
PE20070978A1
(en)
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks)
|
BRPI0710110A2
(en)
|
2006-03-31 |
2011-08-02 |
Novartis Ag |
organic compounds
|
CA2647448A1
(en)
|
2006-04-12 |
2007-10-18 |
Pfizer Limited |
Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
|
WO2007144394A2
(en)
|
2006-06-16 |
2007-12-21 |
High Point Pharmaceuticals, Llc. |
Pharmaceutical use of substituted piperidine carboxamides
|
ES2340093T3
(en)
|
2006-06-22 |
2010-05-28 |
Biovitrum Ab (Publ) |
PIRAZINE AND PIRIDINE DERIVATIVES AS INHIBITORS OF CINASA MNK.
|
FR2903101B1
(en)
|
2006-06-30 |
2008-09-26 |
Servier Lab |
NOVEL NAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
|
US20080021026A1
(en)
|
2006-07-20 |
2008-01-24 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
EP1903038A1
(en)
|
2006-09-07 |
2008-03-26 |
Bayer Schering Pharma Aktiengesellschaft |
N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators
|
EP2061462A2
(en)
|
2006-09-15 |
2009-05-27 |
Schering Corporation |
Treating pain, diabetes and lipid metabolism disorders
|
WO2008112440A1
(en)
|
2007-03-09 |
2008-09-18 |
Astrazeneca Ab |
Piperazine and piperidine mglur5 potentiators
|
JP5496877B2
(en)
|
2007-04-16 |
2014-05-21 |
アッヴィ・インコーポレイテッド |
7-substituted indole Mcl-1 inhibitors
|
BRPI0909212A2
(en)
|
2008-03-28 |
2015-08-18 |
Pacific Biosciences California |
Compositions and method for nucleic acid sequencing
|
EP2133334A1
(en)
|
2008-06-09 |
2009-12-16 |
DAC S.r.l. |
Heterocyclic derivatives as HDAC inhibitors
|
US8507491B2
(en)
|
2008-08-25 |
2013-08-13 |
Irm Llc |
Compounds and compositions as hedgehog pathway inhibitors
|
CA2743134A1
(en)
|
2008-11-10 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
WO2010087399A1
(en)
|
2009-01-30 |
2010-08-05 |
第一三共株式会社 |
Urotensin-ii receptor antagonists
|
ES2436550T3
(en)
|
2009-04-20 |
2014-01-02 |
F. Hoffmann-La Roche Ag |
New proline derivatives as cathepsin inhibitors
|
AR076376A1
(en)
|
2009-04-22 |
2011-06-08 |
Janssen Pharmaceutica Nv |
AZETIDINIL DIAMIDS AS INHIBITORS OF MONOACILGLICEROL LIPASA
|
US20120083476A1
(en)
|
2009-06-05 |
2012-04-05 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
|
EP2270002A1
(en)
|
2009-06-18 |
2011-01-05 |
Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg |
Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
|
ES2618630T3
(en)
|
2009-06-29 |
2017-06-21 |
Agios Pharmaceuticals, Inc. |
Therapeutic compositions and related methods of use
|
WO2011016559A1
(en)
|
2009-08-07 |
2011-02-10 |
武田薬品工業株式会社 |
Heterocyclic compound and use thereof
|
KR101256018B1
(en)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
|
US20110230476A1
(en)
|
2009-09-09 |
2011-09-22 |
Avila Therapeutics, Inc. |
Pi3 kinase inhibitors and uses thereof
|
AU2010341573B2
(en)
|
2009-12-22 |
2016-10-13 |
Vertex Pharmaceuticals Incorporated |
Isoindolinone inhibitors of phosphatidylinositol 3-kinase
|
CN102812167A
(en)
|
2009-12-30 |
2012-12-05 |
阿维拉制药公司 |
Ligand-directed Covalent Modification Of Protein
|
US8722663B2
(en)
|
2010-01-29 |
2014-05-13 |
Otsuka Pharmaceutical Co., Ltd. |
Di-substituted pyridine derivatives as anticancers
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
EP2547664B1
(en)
|
2010-03-16 |
2016-05-04 |
Merck Patent GmbH |
Morpholinylquinazolines
|
RU2012136643A
(en)
|
2010-04-28 |
2014-06-10 |
Дайити Санкио Компани, Лимитед |
[5,6] - HETEROCYCLIC COMPOUND
|
TW201202230A
(en)
|
2010-05-24 |
2012-01-16 |
Mitsubishi Tanabe Pharma Corp |
Novel quinazoline compound
|
WO2011153553A2
(en)
|
2010-06-04 |
2011-12-08 |
The Regents Of The University Of California |
Methods and compositions for kinase inhibition
|
EP2580378A4
(en)
|
2010-06-08 |
2014-01-01 |
Nugen Technologies Inc |
Methods and composition for multiplex sequencing
|
US8658131B2
(en)
|
2010-06-21 |
2014-02-25 |
Washington University |
Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand
|
RU2582610C2
(en)
|
2010-07-30 |
2016-04-27 |
Онкотерапи Сайенс, Инк. |
Quinoline derivatives and melk inhibitors containing same
|
CN103068798A
(en)
|
2010-09-03 |
2013-04-24 |
詹森药业有限公司 |
Di-azetidinyl diamide as monoacylglycerol lipase inhibitors
|
AR083199A1
(en)
|
2010-09-29 |
2013-02-06 |
Intervet Internationale B V |
N-HETEROARILO COMPOUNDS WITH CYCLE BRIDGE UNIT
|
JP2013540159A
(en)
|
2010-10-22 |
2013-10-31 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Piperidin-4-yl-azetidine diamide as monoacylglycerol lipase inhibitor
|
EP2635279A4
(en)
|
2010-11-05 |
2014-10-29 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compounds
|
US9260484B2
(en)
|
2011-06-15 |
2016-02-16 |
Ohio State Innovation Foundation |
Small molecule composite surfaces as inhibitors of protein-protein interactions
|
CA2840627A1
(en)
|
2011-06-29 |
2013-01-03 |
Otsuka Pharmaceutical Co., Ltd. |
Quinazolines as therapeutic compounds and related methods of use
|
CN103087077B
(en)
|
2011-11-03 |
2016-05-18 |
上海希迈医药科技有限公司 |
Thienopyrimidine and furans miazines derivative, its preparation method and in application pharmaceutically
|
JP2013107855A
(en)
|
2011-11-22 |
2013-06-06 |
Mitsubishi Tanabe Pharma Corp |
Pharmaceutical composition
|
US9745631B2
(en)
|
2011-12-20 |
2017-08-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
WO2013096151A1
(en)
|
2011-12-22 |
2013-06-27 |
Glaxosmithkline Llc |
Chemical compounds
|
ES2575604T3
(en)
|
2012-01-13 |
2016-06-29 |
Bristol-Myers Squibb Company |
Thiazolyl or thiadiazolyl substituted pyridyl compounds useful as kinase inhibitors
|
WO2013140148A1
(en)
|
2012-03-19 |
2013-09-26 |
Imperial Innovations Limited |
Quinazoline compounds and their use in therapy
|
WO2013155077A1
(en)
|
2012-04-09 |
2013-10-17 |
Board Of Regents,The University Of Texas System |
Response markers for src inhibitor therapies
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
AR091004A1
(en)
|
2012-05-09 |
2014-12-30 |
Gradalis Inc |
RNA IN SHORT BIFUNCTIONAL FORK (BI-ARNHC) SPECIFIC OF INDIVIDUAL NUCLEOTID MUTATIONS IN K-RAS
|
JO3300B1
(en)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
Compounds and compositions for modulating egfr activity
|
CN109627239B
(en)
|
2012-07-11 |
2021-10-12 |
缆图药品公司 |
Inhibitors of fibroblast growth factor receptors
|
TW201414737A
(en)
|
2012-07-13 |
2014-04-16 |
必治妥美雅史谷比公司 |
Imidazotriazinecarbonitriles useful as kinase inhibitors
|
CA2882879A1
(en)
|
2012-08-24 |
2014-02-27 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
US20150283142A1
(en)
|
2013-03-15 |
2015-10-08 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
MX2015006152A
(en)
|
2012-11-20 |
2016-01-20 |
Genentech Inc |
Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants.
|
JP6464139B2
(en)
|
2013-03-14 |
2019-02-06 |
コンバージーン・リミテッド・ライアビリティ・カンパニーConvergene Llc |
Methods and compositions for inhibition of bromodomain-containing proteins
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
MX364438B
(en)
|
2013-03-15 |
2019-04-26 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c.
|
KR20160003647A
(en)
|
2013-03-15 |
2016-01-11 |
에피자임, 인코포레이티드 |
Carm1 inhibitors and uses thereof
|
JP6518656B2
(en)
|
2013-06-13 |
2019-05-22 |
バイオデシー, インコーポレイテッド |
Method of screening candidate biochemical entities targeting a target biological entity
|
US20150005277A1
(en)
|
2013-06-28 |
2015-01-01 |
Beigene, Ltd. |
Protein Kinase Inhibitors and Uses Thereof
|
KR102325247B1
(en)
|
2013-07-03 |
2021-11-11 |
카리오팜 쎄라퓨틱스, 인코포레이티드 |
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
|
ES2706150T3
(en)
|
2013-07-31 |
2019-03-27 |
Merck Patent Gmbh |
Pyridines, pyrimidines and pyrazines, as inhibitors of BTK and their uses
|
CN104418860B
(en)
|
2013-08-20 |
2016-09-07 |
中国科学院广州生物医药与健康研究院 |
Pyrimido heterocycle compound and Pharmaceutical composition thereof and application
|
BR112016008016B8
(en)
|
2013-10-10 |
2023-09-26 |
Araxes Pharma Llc |
kras g12c inhibitory compounds, pharmaceutical composition comprising said compounds, methods for regulating the activity and for preparing a kras, hras or nras g12c mutant protein, method for inhibiting the proliferation of a population of cells and therapeutic uses of said compounds
|
JO3805B1
(en)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c
|
US9376559B2
(en)
|
2013-11-22 |
2016-06-28 |
Exxonmobil Chemical Patents Inc. |
Reverse staged impact copolymers
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
MX2016009403A
(en)
|
2014-02-03 |
2016-09-16 |
Cadila Healthcare Ltd |
Heterocyclic compounds.
|
AU2015231202B9
(en)
|
2014-03-20 |
2019-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
BR112016021730B1
(en)
|
2014-03-24 |
2022-09-06 |
Guangdong Zhongsheng Pharmaceutical Co., Ltd |
QUINOLINE DERIVATIVES AS SMO INHIBITORS
|
EP3148981A4
(en)
|
2014-05-30 |
2017-11-08 |
The Trustees of Columbia University in the City of New York |
Multivalent ras binding compounds
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US20170305922A1
(en)
|
2014-09-17 |
2017-10-26 |
Epizyme, Inc. |
Carm1 inhibitors and uses thereof
|
JO3556B1
(en)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
Combination therapies for treatment of cancer
|
EP3197870B1
(en)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
CN106852142B
(en)
|
2014-10-08 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
Spirodiamine derivatives as aldosterone synthase inhibitors
|
CN107278202A
(en)
|
2015-01-23 |
2017-10-20 |
融合生命科学公司 |
Heterocycle ITK inhibitor for treating inflammation and cancer
|
EA201792214A1
(en)
*
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
COMPOUNDS OF SUBSTITUTE QUINAZOLINE
|
ES2856880T3
(en)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
KRAS Condensed Tricyclic Inhibitors and Methods of Using Them
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
EP3325447A1
(en)
|
2015-07-22 |
2018-05-30 |
Araxes Pharma LLC |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
MX2018004643A
(en)
|
2015-10-21 |
2018-08-01 |
Otsuka Pharma Co Ltd |
Benzolactam compounds as protein kinase inhibitors.
|
AU2016355433C1
(en)
|
2015-11-16 |
2021-12-16 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
JP2019534260A
(en)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Heterocyclic compounds as inhibitors of RAS and methods of use thereof
|
DK3534899T3
(en)
|
2016-11-03 |
2022-06-20 |
Corvus Pharmaceuticals Inc |
CONNECTIONS AND METHODS OF MODULATING INTERLEUKIN-2 INDUCERABLE T-CELL KINKASE
|
CN110382482A
(en)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
Condensed miscellaneous-Heterobicyclic compounds and its application method
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
JP2020505395A
(en)
|
2017-01-26 |
2020-02-20 |
アラクセス ファーマ エルエルシー |
Fused N-heterocyclic compounds and methods of use
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
JOP20190186A1
(en)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
Quinazoline compound
|
TW201906832A
(en)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
Compounds for cancer treatment and methods of use thereof
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
BR112019024674A2
(en)
|
2017-05-25 |
2020-06-16 |
Araxes Pharma Llc |
COVALENT KRAS INHIBITORS
|
JP7266043B2
(en)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C inhibitors and methods of using them
|
CN112584833A
(en)
|
2018-08-01 |
2021-03-30 |
亚瑞克西斯制药公司 |
Heterocyclic spiro compounds and methods of use thereof for treating cancer
|
MX2021004624A
(en)
|
2018-10-24 |
2021-05-27 |
Araxes Pharma Llc |
2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl) -benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis.
|
WO2020113071A1
(en)
|
2018-11-29 |
2020-06-04 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|